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Abstract. In this report, we describe the 
coexistence of two rare and debated com-
plications of hepatitis C virus (HCV) infec-
tion: interstitial nephritis, with associated 
focal glomerulosclerosis, and autoimmune 
hepatitis, in a 55-year-old HIV/HCV-co-
infected woman. The patient was treated for 
the immune-mediated manifestations with 
mycophenolate mofetil, which she continued 
for 9 years, as symptoms relapsed at every 
attempt to discontinue immunosuppression. 
The patient finally cleared HCV infection 
thanks to new direct-acting agents and could 
discontinue immunosuppressive therapy 
maintaining stable conditions and laboratory 
parameters after 24-weeks follow-up.
Introduction
Hepatitis C virus (HCV)-infected patients 
are a population at risk of viral-related liver 
complications, such as fibrosis, cirrhosis, and 
hepatocellular carcinoma (HCC) [1]. More-
over, immune-mediated extra-liver complica-
tions are also possible [2], and among these, 
renal complications are frequent [3]. The 
renal diseases mainly associated with HCV 
infection are membranoproliferative glomer-
ulonephritis, but also membranous nephropa-
thy, IgA nephropathy, proliferative glomeru-
lonephritis, interstitial nephritis, and focal 
segmental glomerulosclerosis [4]. In human 
immunodeficiency virus (HIV)-infected pa-
tients, other risks factors for development of 
renal disease are also present, related to HIV 
infection itself, but also to some antiretro-
viral therapies [5, 6]. In patients coinfected 
with HIV/HCV, the causes of renal damage 
cumulate, creating a pairing of viral infection 
and renal disease that is commonly observed, 
but not inseparable. The availability of new 
direct-acting antivirals (DAAs) has changed 
the prognosis of HCV infection, increasing 
significantly efficacy and safety compared to 
pegylated interferon (pegIFN)-based treat-
ment [3]. However, data regarding the out-
come of renal extrahepatic diseases associ-
ated with HCV are still scarce. In this report, 
we describe the outcome of a severe intersti-
tial nephritis following HCV treatment with 
DAA in an HIV/HCV-coinfected patient and 
a review of the inherent literature.
Clinical case
A 55-year-old woman, with HIV/HCV 
(genotype 3a) coinfection diagnosed in 1991, 
and previous intravenous drug user, has been 
followed by our outpatient department since 
1998. The patient had been treated with 
 antiretrovirals since 1991, with a good immu-
novirologic response. In 2005, she received 
anti-HCV therapy with pegIFN and ribavirin 
for 24 weeks, but the HCV infection relapsed 
after treatment discontinuation. Hereafter, 
she regularly followed her antiretroviral ther-
apy and had an HIV-RNA load persistently < 
50 copies/mL and stable clinical condition. 
Despite this, in summer 2007, she developed 
two consecutive episodes of acute kidney in-
jury (AKI) associated with cholestatic acute 
hepatitis. At the time of her first hospital 
Clinical Nephrology – Case Studies, Vol. 6/2018 (31-35) 
©2018 Dustri-Verlag Dr. K. Feistle 
ISSN 2196-5293 
DOI 10.5414/CNCS109221
e-pub: October 26, 2018
Mirabella, Taramasso, Nicolini, et al. 32
admission, her antiretroviral therapy (ART) 
with tenofovir disoproxil fumarate 245 mg 
q.d., lamivudine 300 mg q.d., and fosampre-
navir 700 mg b.i.d. was stopped, in the sus-
picion of possible renal damage. Blood tests 
revealed acute kidney failure, with a serum 
creatinine level of 6.3 mg/dL associated with 
blood urea nitrogen 67 mg/dL and uric acid 
10.6 mg/dL. Other notable results were hy-
perbilirubinemia (19.8 mg/dL, normal range 
0.20 – 1.20 mg/dL), hepatic failure, with a 
coagulative deficit (prothrombin time 25), 
and metabolic acidosis. Anti-smooth-muscle-
antibodies (ASMA) were positive (160 : 1), 
while antinuclear antibodies (ANA), anti-
bodies directed against proteins that bind 
to nucleic acids (ENA), antibodies directed 
against phospholipids and antineutrophil 
cytoplasmic (ANCA), adrenal cortex anti-
bodies (ACA), antimitochondrial antibodies 
(AMA), and anti-liver-kidney microsomal 
(ALKM) antibody were negative. Urinalysis 
showed proteinuria, hematuria, and pyuria. 
Abdomen ultrasound showed a liver enlarge-
ment without focal lesions, a modest ascites, 
and enlarged kidneys with an increment of 
arterials resistances. The patient’s manage-
ment required hemodialysis, albumin, vi-
tamin K, and human plasma. At the same 
time, the patient started methylprednisolone 
therapy (250 mg daily, then reduced to 40 
mg daily). After clinical and chemistry im-
provement, the patient was discharged with 
oral steroid treatment (prednisone 25 mg dai-
ly), which was subsequently tapered. Three 
months later, after steroid discontinuation 
and ART still discontinued, a new onset of 
AKI (serum creatinine levels 6.0 mg/dL) re-
quired hospital admission. A kidney biopsy 
was performed showing tubule-interstitial 
nephritis and focal glomerulosclerosis (Fig-
ure 1). Blood tests confirmed the presence 
of ASMA antibodies as well as negativity 
for ANA, ENA, p-ANA, c-ANCA, LKM 
(liver-kidney microsomal), ACA, and AMA. 
Then, methylprednisolone 40 mg daily was 
restarted with success (Serial serum creati-
Figure 1. Biopsy specimen with a portion of renal 
cortical and medulla containing 12 glomeruli, 2 of 
which were sclerotic. Three glomeruli presented 
slight segmental mesangial sclerosis, 2 others pre-
sented mesangial sclerosis and irregular thicken-
ing of blood vessel walls (due to ischemia). Diffuse 
edema, interstitial fibrosis, focal atrophy, and tubu-
lar deterioration were present among with diffuse 
lymphomonocytic infiltration with infiltration of the 
tubular tissue. Arteriosclerosis was present. Im-
munofluorescence tests were negative. Electronic 
microscopy was not performed. The specimen was 
compatible with FSGS and interstitial nephritis.
Table 1. Patient therapies before, during, and after HCV eradication treatment with direct acting agents 
(DAA). Antiretroviral drugs are highlighted in bold.
Pre-eradication therapy During eradication with DAA After eradication
MMF 1 g b.i.d.
Nebivolol 5 mg o.d.
Darunavir 600 mg b.i.d.
Ritonavir 100 mg b.i.d.
Etravirine 100 mg b.i.d.
Maraviroc 150 mg b.i.d.
Lorazepam 2.5 mg o.d.
Amitriptyline 60 mg o.d.
MMF 1 g b.i.d.
Nebivolol 5mg o.d.
Darunavir 600 mg b.i.d.
Ritonavir 100 b.i.d.
Etravirine 100 mg b.i.d.
Sofosbuvir 400 mg o.d.
Daclatasvir 60 mg o.d.
Lorazepam 2.5 mg o.d.
Amitriptyline 30 mg o.d.
RPV/FTC/TDF o.d.
Atenolol 100 mg o.d.
MMF = mycophenolate mofetil; RPV/FTC/TDF = rilpivirine/emtricitabine/tenofovir disoproxil fumarate; 
b.i.d. = bis in die; o.d. = once daily.
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nine levels are reported in Figure 2). At dis-
charge, oral prednisone (37.5 mg daily) was 
prescribed, and it was tapered over a period 
of 4 weeks. In January 2008, considering the 
progressive improvement of renal function 
(creatinine 1.0 mg/dL), the consultant ne-
phrologist suggested stopping steroid treat-
ment and starting maintaining treatment with 
mycophenolate mofetil (MMF), 1,000 mg 
b.i.d. Following the starting of MMF, the 
patient exhibited negative ASMA antibodies.
She also restarted ART with abacavir 
300 mg b.i.d., lamivudine 150 mg b.i.d., and 
lopinavir/ritonavir 400/100 b.i.d.. MMF was 
continued with good adherence and tolerance 
until November 2009, when, after 2 years of 
good clinical condition, it was discontinued. 
Four weeks after the suspension of MMF, 
the patient experienced a new deterioration 
of liver and renal function that required the 
reintroduction of MMF, at a dosage of 500 
mg b.i.d., and new hospital admission (Fig-
ure 1). In the following years, she contin-
ued ART, switching to darunavir/ritonavir 
(800/100 mg), etravirine 200 mg × 2, and 
maraviroc 150 mg × 2 and continued MMF. 
In June 2012, a new episode of cholestatic 
hepatitis developed, without renal involve-
ment. A liver biopsy was obtained showing 
coexisting chronic HCV-related hepatitis and 
autoimmune hepatitis. Immunosuppressive 
therapy was enhanced with steroidal thera-
py (1 mg/kg), but she refused to continue. 
Thus, she was put on an increased dosage of 
MMF, of 1,000 mg b.i.d.. This therapy was 
continued in the following years with im-
provement of renal and hepatic parameters. 
In September 2015, the patient received 
anti-HCV treatment with sofosbuvir 400 mg 
q.d. plus daclatasvir 60 mg q.d. for 12 weeks 
without ribavirin. Before the starting of HCV 
treatment, maraviroc was stopped to avoid 
expected drug-drug interaction. Sustained 
virological response (SVR) was achieved, 
and, 3 months later, in agreement with the 
nephrologists, the patient halved the MMF 
dosage, and stopped it after other 12 weeks. 
Subsequent blood tests showed a permanent 
negativity of HCV-RNA load, with creati-
nine and hepatic enzymes persistently within 
the normal range (creatinine persistently 
< 0.95 mg/dL, and bilirubin < 1.20 mg/dL) 
and negative ASMA antibodies 12 months 
after MMF suspension. Since the patient no 
longer needed to keep an NRTI-sparing regi-
men, a single-tablet-regimen with rilpivirine/
emtricitabine/tenofovir disoproxil fumarate 
was reintroduced.
Discussion
In this report, we described the coexis-
tence of two rare and debated complications 
of HCV infection in an HIV/HCV coinfected 
woman: interstitial nephritis, with associated 
focal glomerulosclerosis, and autoimmune 
hepatitis. Pathogenesis of autoimmune hepa-
titis is still incompletely understood, but it 
involves genetic, both immune and nonim-
Figure 2. Serial serum creatinine and total bilirubin levels are reported with regard to immunosuppressive 
and anti-HCV treatment.
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mune, and environmental triggering factors. 
While HCV has long been associated with 
the induction of autoimmune disorders, it 
can potentially cause both glomerular and 
tubulointerstitial diseases, although focal 
segmental glomerulosclerosis and acute in-
terstitial nephritis (AIN) have been rarely 
reported [4, 7, 10, 11, 12]. The finding of 
molecular mimicry by cross-reactivity be-
tween epitopes of HCV and liver antigens 
tends to give weight to the argument that au-
toimmune hepatitis may be triggered by viral 
hepatitis [13].
As all viruses may potentially trigger au-
toimmune diseases, the possible role of HIV 
infection has been evaluated. However, the 
patient developed the first episode of AKI 
when she had good immune-virological con-
trol of HIV with c-ART. Thus, we excluded 
the role of HIV infection in the present case.
Beyond viruses, another possible cause 
for AIN is drug-induced damage. Indeed, 
many drugs, such as antibiotics, nonsteroidal 
anti-inflammatory drugs (NSAIDs), and an-
tiretroviral drugs (e.g., indinavir, abacavir, 
ritonavir, and atazanavir), have been associ-
ated with AIN [8]. For this reason, during the 
first onset of AKI, the patient discontinued 
cART, but, she developed a second episode 
of AKI and she was not taking cART or any 
other drug associated with the risk of AKI. 
Additionally, despite it being previously re-
ported in her medical history, the patient had 
not used recreational drugs for many years 
before the onset of AKI [9]. Thus, in the 
present case, HCV is the most probable trig-
ger for autoimmune disease.
Current guidelines suggest the correction 
of risk factors in case of secondary disease 
[14], but in our case, the patient had al-
ready stopped intravenous drugs abuse and 
achieved HIV-RNA suppression with ART 
when symptoms appeared. Additionally, ste-
roid treatment is recommended as the first-
line regimen for autoimmune renal diseases, 
and it may be withdrawn after a period of 
clinical stability, as it can lead to remission 
[15]. When steroids fail or disease relapses, 
it is possible to switch immunosuppressive 
therapy to a cytotoxic agent (cyclophospha-
mide, chlorambucil, or MMF) or calcineu-
rin inhibitors (cyclosporin A or tacrolimus). 
We chose MMF due to the reduced risk of 
pharmacological interactions. Immunosup-
pressive therapy with a cytotoxic agent or 
a calcineurin inhibitor can be stopped after 
1 – 2 years if remission has been maintained 
[16]. Of note, before HCV eradication, we 
attempted to stop MMF after 2 years of 
continuous treatment, but our patient expe-
rienced a relapse of renal and liver disease 
within 4 weeks from suspension. On the oth-
er hand, following HCV eradication, MMF 
discontinuation was safe, and the patient did 
not experience any deterioration of liver and 
renal function, and ASMA antibodies re-
mained undetectable until the last available 
follow-up.
Despite anecdotal experiences showing a 
favorable impact of SVR on HCV-associated 
kidney diseases [11, 16, 17, 18], few cases of 
long-term responders in interstitial nephritis 
after HCV infection eradication have been 
reported so far, and none of them following 
treatment with DAAs [11, 17, 18]. In sum-
mary, our patient developed stable and off-
treatment remission of interstitial nephritis 
following SVR with DAAs. HCV eradica-
tion following treatment with DAAs did not 
negatively impact on autoimmune hepatitis, 
and also, we shut down the trigger of renal 
disease. We believe this case provides further 
insight into whether DAA treatment may im-
pact on the outcome of patients with extra-
hepatic liver diseases.
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